Overview
Horner's syndrome is characterized by ptosis, miosis, and anhidrosis resulting from disruption of the sympathetic pathway, typically at the level of the first-order (nerve root), second-order (sympathetic chain), or third-order (lateral horn of the spinal cord to the superior cervical ganglion) neurons. 1Diagnosis
Clinical Presentation: Assess for ptosis, miosis, and absence of sweating on the affected side.
Pharmacologic Testing: Hydroxyamphetamine (Paredrine) test can localize the lesion; however, false-negatives may occur in the first week post-injury due to temporary loss of presynaptic terminal function. 1
Imaging: Neuroimaging (e.g., MRI, CT) is crucial for confirming the level of lesion involvement. 1Management
Supportive Care: Focus on managing symptoms and addressing underlying causes.
Specific Treatments: No specific pharmacological treatments are universally recommended; management is largely directed at the underlying cause (e.g., tumor resection, vascular repair).Special Populations
No Specific Guidance: The provided abstracts do not cover special populations such as pregnancy, pediatrics, elderly, or specific comorbidities.Key Recommendations
Perform pharmacologic testing with hydroxyamphetamine cautiously, recognizing potential false-negative results in the first week post-symptom onset due to temporary presynaptic dysfunction. (Evidence: Weak) 1
Utilize neuroimaging to accurately localize the site of lesion in Horner's syndrome for targeted management. (Evidence: Moderate) 1
Tailor management strategies to address the underlying cause of Horner's syndrome rather than specific symptomatic treatments. (Evidence: Expert opinion) 1References
1 Donahue SP, Lavin PJ, Digre K. False-negative hydroxyamphetamine (Paredrine) test in acute Horner's syndrome. American journal of ophthalmology 1996. link70395-2)